Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What is the purpose of this? What does this hope to accomplish? What is the objective? The purpose?
Business as Usual. Just a negotiating strategy by the unions and management. Pilots what huge pay raises. They've been negotiating this contract agreement for 3 years. American Airlines expects to see record sales over the upcoming holidays.
govs... I'm optimistic that we'll see .22 again. And we'll see .17 again too. Great for swing trading.
Well ReviveThomas ... how did your prediction work out for you. Weeks? That prediction was in Jan 2022. As I've said many times, this is a great stock for swing trading! Long term, it will most likely turn out to be a covid19 flop just like the rest of the small biotechs with big promises. Mostly because M.F. has been in love with shrooms right from the get go. Even if this drugs works, it's too little too late. In the meantime, I'm still swinging away! JMHO.
I must admit though that the new 15c2-11 ruling has muddied the waters a bit. I'm not sure if the SEC delisting policy includes the expert market or not. But in the grand scheme of things it's a moot point if someone is trying to sell their shares when there is virtually no volume.
Sorry, that will never happen. 2 years from now this ticker will most likely be hanging around attracting newcomers look for a new opportunity. The incumbent SH will be long gone. That's how it works in penny world. Tickers just don't disappear overnight unless there is a change of some sort initiated by the insiders. The SEC doesn't go around shutting down penny stocks. They simply do not have the resources for that. If you make an inquiry with them, they usually just say.... "Buyers Beware with penny stocks". They have no sympathy for SH who are looking for get rich quick penny stocks.
Mountain... not very much at all (compared to you). So I understand why you are frustrated. Considering how low the float and o/s were (once upon a time), I'm surprised that mgmt got so easily derailed by not being able to process simple paperwork. This stock had a lot of promise IMO. Clearly, we do not know the full story regarding what happened. We may never know.
pegs...where are you seeing RLFTF stating that they are in Phase 2 trials with aviptadil? Are you referring to the inhaler trial?
We are waiting for the NIH to release the data on that puzzling trial.
We are also getting close for the results from the Dr. Jörg Leuppi inhaler phase 2 trial (Dec 2022). It says 82 patients, but I'm pretty sure they have increased that size to 132 patients.
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
https://clinicaltrials.gov/ct2/show/NCT04536350
As an innocent person, I would never want you on my jury. Innocent until proven guilty pertains to all.
My home handy man's name is Tom Nelson (I'm not kidding).
10/10/22 - Relief Announces U.S. Launch of PKU GOLIKE
https://relieftherapeutics.com/newsblog-detail/?newsID=2357931
Jedi... wow, you hit that one at the bullseye!!! The FDA did indeed throw a major curve ball at QNTA.
I've always been of the opinion that the President should appoint an independent 'oversight' team over the FDA decision makers to help weed out incompetence and corruption.
There is ample evidence that there is sizable corruption via the PDFA (act). On the $ take! Particularly with big pharma.
And considering the high volume of FDA drug recalls (due to safety), there is also ample evidence of incompetence IMO. Last year one of the key FDA decision makers resigned because his FDA team approved an Alzheimer's drug that missed it's primary endpoints and showed very little efficacy. He was so disgusted that he walked off. My guess is the lucrative PDFU fees enticed them into approving it.
Shoondale... would you please post specific, concrete evidence that you have in your possession that proves (without a doubt) that QNTA scammed their investors. Missing SEC filing dates does not qualify as a scam. And speculating by trying to read between the lines on a financial statement does not count either. Please post concrete PROOF that they are a scam by including specific links or SEC / law enforcement phone numbers who will testify that QNTA is a scam. Thank you in advance.
Mountain.. I have to strongly agree with you on this point. They should issue a PR providing the SH with an update as well as their future plans. They can always state that they are not at liberty to comment on the SEC investigation. However, they should at least provide an update on business operations and their future plans.
Is it possible that the SEC placed a gag order on them? I would not think so.
Maybe they will read my post.
Copy That!
In at .16, out at .22 37% ROI. Very nice.
It's not so obvious to many. I highly suspect that you are betting your farm on this one. Like many others. Lot of headstones scattered about in penny land. Possibly RVVTF will be different. The probabilities say that it won't be any different. Yes, I've been around here for quite a while... swing trading this puppy.
Rick..yes, like I did with RLFTF. Diversify. Don't put all of your eggs in one basket. RLFTF is a great example of everyone having extremely high hopes, only to be dashed by trials that did not meet expectation.
mrpenny...RVVTF is a very good stock for swing trading though. Whether the true longs get rewarded over the long term is anyone's guess. And true longs that are putting all of their eggs in one basket is a very bad, risky move though. To each his/her own though. JMHO
pegs, I have no crystal ball. But I was hoping that ACER would have been ready for it's June 5 PDUFA event, but they weren't. So that is pushed off to mid January 2023. If the FDA approves their drug then that would generate a revenue stream for RLFTF which should give the pps a small boost.
NASDAQ...I'm still convinced that RAM is doing the ADR so that he will have another mechanism to dilute (by selling ADRs). He must wait until Level 3 is reached though before he can dilute like that. The big question for me is..... what impact will diluting per ADR selling have on the underlying stock (RLFTF)? Just don't know. But if we are forced to convert our OTC shares to ADR, then it is a moot point. We will then be at the mercy of the NASDAQ market place with the ADRs. Even if there is no RAM driven ADR dilution, then IMO we will still need a positive stream of good news being PR'd to sustain the new higher (150x) pps on the NASDAQ. And RAM may surprise us with a 250x conversion.
Obtuse... I can't disagree with any of your assessment. As you may know, the PDUFA (act) allows the FDA to collect massive $ fees from drug makers as they sell their drugs. So there is a corrupt incentive for the FDA to approve drugs that will provide them with maximum kickback $$ fees. PDUFA was supposed to accelerate the FDA approval process to more quickly put life saving drugs into the hands of the consumer. Instead..... PDUFA has provided a revenue generating vehicle that the FDA has exploited. Big Pharma clearly has the edge for approvals ...thanks to PDFUA. PDUFA should be killed IMO.
Mountain.. no one is justifying their actions. The problem is --- there is nothing we can do. So I am not going to grieve over it. If QNTA can pull a rabbit out of their hat by securing a deal with some partner, then that would be great. Else... my whole life does not revolve around QNTA. And nagging the SEC to crush QNTA will serve no useful purpose for the the incumbent shareholders.
BTW, the SEC is not going to put anyone in jail. The SEC will simply tell you to never put your hard earned $$ into a risky, unproven penny stock. And they don't have the resources to chase down every penny stock scam on the OTC. So that will never happen. Rather the SEC states.... "Buyers Beware".
Diversification is the key to surviving investments in penny stocks. The vast majority are losers, but occasionally you get a big winner.
Mrpenny.... recent events certainly cast some very dark shawdows! Tiny biotechs tend to be very volatile, and they die a very slow death with the investor pain lingering for several years. However, I'm not quite there yet with RVVTF. They are trying to navigate new FDA hurdles, and we'll see how effective they can do that. RLFTF was unsuccessful with navigating those FDA hurdles and that stock pps finally tanked.
There is still some hope left for RVVTF IMO. But as I've posted many times, I don't believe MIchael Frank is very effective at driving this boat, and he's had his priorities all screwed up from the very beginning IMO. He's a shroom guy. Several years ago I also discovered that Michael has been associated with performing a R/S with another company. So as the O/S and float grow with RVVTF, I do fear he'll eventually resort to that as a means to help raise funds. Time will tell.
Jedi.. you bring up some very good points (cost of RE in CA, working from home, etc). The landscaping looks pretty well kept as well. It's a non-issue IMO.
You will only shoot yourself in the foot by encouraging the SEC to delist QNTA.
Mountain ... why would you encourage the SEC to delist QNTA? Wouldn't that result in your losing all of your equity for sure?
Buy now at .18, sell at .26 sometime over the next 20-30 days = 44% ROI. That's nice by any standard. That's not flipping. That's a form of swing trading.
Antler... yes, mark my post. I stand by my words. GLTA
It's Analysis/Paralysis. The FDA moves at it's own slow pace. Especially with small, foreign penny stocks. Unfortunately.
The only short term hope for an ROI with this is if the DSMB declares the trial as overwhelmingly positive. IMO if bucillamine was in fact a winner today, then why are they trying to redefine the goal posts for the trial? There are some trial data issues, and the FDA is notorious for being a stickler with details. Especially with a very small, foreign-based penny stock. I see this dragging out into 2024.
Those that have been swing trading this stock over the past two years have made a small fortune! Kudos to them! Long term investors carry much more risk. The final FDA decision on this can go either way (50/50), and the FDA works very slow (unless you are Big Pharm). JMHO
I always speak the truth. No pump. No bash. I've been around this board for a longgg time. I've been in and out of RVVTF. IMO RVVTF is very good for swing trading. It's not ready yet for long term investing due to all of the uncertainties surrounding the FDA. I've been down this road many times with other 'little' wantabe penny stocks.
I raised the red flag way back when I noticed the Mike was unprepared to kick off Phase 3 trials. After the FDA gave the green light, Mike did nothing for months!! He knew it was coming with a high probability), yet he was consumed by "Shrooms". He gave shrooms higher priority than bucillamine. That was my red flag way back then, and I posted my feelings on that way back then as well. He's only recently came around to taking this trial seriously. He's also a very poor speaker, and doesn't know how to market his own product let along promote his own business to investors. Fortunately the O/S and Float are not off the map (yet), so there is hope without the R/S. JMHO.
You honestly believe that the DSMB is on the verge of announcing tat this drug had met all of it's primary goals with safety and efficacy!. Just won't happen this year. And based on the recent FDA response, Mike has a lot of work ahead of him with reshaping this clinical trial to make the FDA happy. IMO they will need to extend the trial to meet the demands of the FDA. All of this take lots of time (unless you are Big Pharma). I've seen this happen too many times. It is what it is. GLTA
A long and winding road for RVVTF with the FDA. This is beginning to behave like the last 2 years of RLFTF. I predict that this study and subsequent potential FDA drug approval will run deep into 2024. The only hope is if RVVTF can convince the FDA to agree with new and different trial target goals. Dealing with the FDA is a time consuming mess, unless you are Big Pharma with resources and political clout. JMHO
Jedi, I understand your Apple analogy. I agree with you. What you say makes perfect sense to me. GLTA
Yes, and most important....the financing allows TSOI to forge ahead with Phase 3 FDA clinical trials. That's the bottom line. Everything else is just noise. This is a long term investment. It's NOT a good swing trade.
I flatly disagree! Anyone who thinks they are going to make a solid ROI by dumping at 1 cent isn't looking at it from a business perspective. If they start dumping at 1 cent, they will quickly be dumping at sub-penny value. That's a losing (poor) business proposition. They will wait for an upward price movement before cashing in on their investment. Otherwise they will destroy their own investment by crushing the PPS.
On the other hand... GHS may plan on holding the shares longer term (as in investment) if they believe in TSOI.
What is difference between BLA and NDA?
To formally request approval to market a new drug in the United States, Sponsors must submit either a New Drug Application (NDA) or a Biologics License Application (BLA) to the FDA. As their names suggest, BLAs relate to biological products while NDAs generally pertain to traditional small molecule drugs.
How long does it take for a BLA to be approved by FDA?
As per the Prescription Drug User Fee Act (PDUFA), the FDA agreed to review the majority of BLAs within 10 months of 60 day filing and for the priority submissions it has been cut down to 6 months of 60 day filing date.
A2Z...IMO it's the ultra high O/S that is holding the pps down. There is no quick solution to that.
It is GREAT news that Tim has now gone public with HOW he will fund Phase 3 of the FDA clinical trials. This has always been an open issue and concern for me. Congratulations to Tim for keeping the shareholders informed !!!